Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abandonment, adequacy, Adriamycin, affirmative, anticancer, Article, ASCO, barrier, basket, BEACOPP, biliary, blood, BrECADD, budget, commonly, Connecticut, contemplated, deprioritize, dexamethasone, dismissed, docetaxel, documentary, DPF, eBEACOPP, emtansine, epidemic, exceeding, expenditure, fourth, German, Jean, letter, lingering, Liu, McDaniel, modernized, Nevada, Nicosia, onsite, Opdivo, ordinary, precluding, procarbazine, pyrexia, satisfaction, Snohomish, suit, SWOG, unprecedented, voluntarily, waiver, Zion
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view